Kura Oncology Reports Second Quarter 2021 Financial Results
August 05, 2021 16:05 ET
|
Kura Oncology, Inc.
– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 – – Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in...
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
August 04, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
July 06, 2021 07:30 ET
|
Kura Oncology, Inc.
– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors – – HNSCC accounts for more than 500,000 new cancer cases each...
Kura Oncology Appoints Carol Schafer to Board of Directors
June 04, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
May 13, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology to Report First Quarter 2021 Financial Results
April 29, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
March 22, 2021 16:08 ET
|
Kura Oncology, Inc.
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS...
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021 07:20 ET
|
Kura Oncology, Inc.
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a...
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
February 24, 2021 07:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Four Upcoming Investor Conferences
February 18, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...